恒瑞医药：注射用SHR-1501纳入突破性治疗名单

Core Viewpoint - The announcement indicates that Shanghai Henlius Biopharma Co., Ltd.'s injectable SHR-1501 has been included in the list of potential breakthrough therapies by the National Medical Products Administration, with a public notice period of 7 days [1] Group 1: Product Information - SHR-1501 is a recombinant interleukin-15 fusion protein developed by the company, which, when used in conjunction with Bacillus Calmette-Guérin (BCG), can enhance immune response and synergistically combat tumors [1] - The primary indication for SHR-1501 is for patients with non-muscle invasive bladder cancer who do not respond to BCG treatment [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-1501 project has reached approximately 102 million yuan [1]